2- (furanyl)- 5- (piperidinyl)- 1- (3,4,5- trimethoxybenzyl)benzimidazole
has antineoplastic activity; structure in first source
Networked: 1
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
Related Diseases
| 1. | Chondrosarcoma
04/01/2012
- " FPipTB-induced apoptosis in human chondrosarcoma cell lines (JJ012 and SW1353) but not in primary chondrocytes. " 04/01/2012
- " In this study, we investigated the anticancer effects of a new benzimidazole derivative, 2-(furanyl)-5-(piperidinyl)- (3,4,5-trimethoxybenzyl) benzimidazole (FPipTB) in human chondrosarcoma cells. " 04/01/2012
- " Thus, FPipTB may be a novel anticancer agent for the treatment of chondrosarcoma." 04/01/2012
- " The results further suggest that FPipTB triggered ER stress, as indicated by changes in cytosolic calcium levels and activated the ASK1-MKK3/6-p38-p53-Bax pathway, causing chondrosarcoma cell death. " 04/01/2012
- " Treatment of chondrosarcoma cells with FPipTB was associated with increased intracellular levels of ASK1, p38, p53, and Bax, followed by release of cytochrome c from mitochondria and activation of caspases. "
|
|
Related Drugs and Biologics